Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts

Key Points

• Analyst consensus is “Hold”: Among nine analysts, four recommend buying Keros Therapeutics, three rate it a hold and two recommend selling. The average 12-month price target is $20.50, above the stock’s reported $11.15 price.
• Recent performance remains weak: Keros reported quarterly EPS of negative $1.45, missing the consensus estimate of negative $1.34, and analysts expect a full-year loss of $5.12 per share.
• Insiders have been selling while institutions hold a majority stake: Company insiders sold 8,425 shares worth about $90,000 during the last quarter, while institutional investors and hedge funds own 71.56% of the stock.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have received an average recommendation of "Hold" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $20.50.

KROS has been the topic of several research reports. Zacks Research lowered shares of Keros Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 29th. Weiss Ratings lowered Keros Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, May 15th. Leerink Partners dropped their price target on Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, August 4th. Wells Fargo & Company cut their price target on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a report on Tuesday, August 4th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $11.15 on Monday. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55. The company has a market capitalization of $221.10 million, a PE ratio of -3.01 and a beta of 0.99. The company has a fifty day moving average of $10.62 and a two-hundred day moving average of $12.35.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, research analysts expect that Keros Therapeutics will post -5.12 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Julius Knowles sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 10,958 shares in the company, valued at approximately $117,579.34. This represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director owned 9,767 shares in the company, valued at $104,702.24. The trade was a 21.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,425 shares of company stock valued at $89,994 in the last quarter. 12.60% of the stock is currently owned by company insiders.

Institutional Trading of Keros Therapeutics

Several large investors have recently bought and sold shares of KROS. Financial Management Professionals Inc. acquired a new stake in shares of Keros Therapeutics during the fourth quarter valued at about $29,000. Caitong International Asset Management Co. Ltd lifted its stake in Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock worth $33,000 after purchasing an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after purchasing an additional 1,888 shares during the period. Lazard Asset Management LLC acquired a new position in Keros Therapeutics in the first quarter worth $129,000. Finally, New York State Common Retirement Fund increased its stake in Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company's stock valued at $142,000 after purchasing an additional 7,700 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source